GNL3 and SKA3 are novel prostate cancer metastasis susceptibility genes

Clinical and Experimental Metastasis

Volumn 32, Issue 8, 2015, Pages 769-782

  Lee, Minnkyong ^a   Williams, Kendra A ^a   Hu, Ying ^b   Andreas, Jonathan ^a   Patel, Shashank J ^a   Zhang, Suiyuan ^a   Crawford, Nigel P S ^a,c  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NONE   (United States)

Author keywords

Genetic susceptibility; Metastasis; Mouse models; Prostate cancer; TRAMP

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MODEL; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CELL MIGRATION; CHROMOSOME 12; CHROMOSOME 14; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE FREE SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOCUS; GENE OVEREXPRESSION; GENETIC SUSCEPTIBILITY; GLEASON SCORE; GNL3 GENE; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MALE; METASTASIS; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE METASTASIS; QUANTITATIVE TRAIT LOCUS; SINGLE NUCLEOTIDE POLYMORPHISM; SKA3 GENE; TUMOR GENE; TUMOR INVASION; ANIMAL; C57BL MOUSE; CELL MOTION; DISEASE MODEL; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; MORTALITY; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

GNL3 PROTEIN, HUMAN; GUANINE NUCLEOTIDE BINDING PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; NUCLEAR PROTEIN; SKA3 PROTEIN, HUMAN;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GTP-BINDING PROTEINS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; QUANTITATIVE TRAIT LOCI;

EID: 84947492602     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-015-9745-y     Document Type: Article

References (45)

1. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA: A Cancer J Clin 65(1):5–29
2. Birkhahn M, Penson DF, Cai J, Groshen S, Stein JP, Lieskovsky G, Skinner DG, Cote RJ (2011) Long-term outcome in patients with a Gleason score
3. Anchi T, Tamura K, Furihata M et al (2012) SNRPE is involved in cell proliferation and progression of high-grade prostate cancer through the regulation of androgen receptor expression. Oncol Lett 3(2):264–268
4. Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI (2012) Do adenocarcinomas of the prostate with Gleason score (GS)
5. Terry S, Beltran H (2014) The many faces of neuroendocrine differentiation in prostate cancer progression. Front Oncol 4:60
6. Karantanos T, Corn PG, Thompson TC (2013) Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 32(49):5501–5511
7. Patel JD, Krilov L, Adams S et al (2014) Clinical cancer advances 2013: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol 32(2):129–160
8. Wang HT, Yao YH, Li BG, Tang Y, Chang JW, Zhang J (2014) Neuroendocrine prostate cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. J Clin Oncol. doi:10.1200/JCO.2013.54.3553
9. Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera JM, Reuter VE, Robinson BD, Troncoso P, Rubin MA (2014) Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol 38(6):756–767
10. Beltran H, Tomlins S, Aparicio A et al (2014) Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res 20(11):2846–2850
11. Berman-Booty LD, Knudsen K (2014) Models of neuroendocrine prostate cancer. Endocr-Relat Cancer. doi:10.1530/ERC-14-0393
12. Tan HL, Sood A, Rahimi HA et al (2014) Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res 20(4):890–903
13. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM (1997) Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 57(21):4687–4691
14. Gingrich JR, Barrios RJ, Foster BA, Greenberg NM (1999) Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis 2(2):70–75
15. Chiaverotti T, Couto SS, Donjacour A, Mao JH, Nagase H, Cardiff RD, Cunha GR, Balmain A (2008) Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol 172(1):236–246
16. Greenberg NM, DeMayo F, Finegold MJ et al (1995) Prostate cancer in a transgenic mouse. Proc Natl Acad Sci United States Am 92(8):3439–3443
17. Zhou Z, Flesken-Nikitin A, Corney DC, Wang W, Goodrich DW, Roy-Burman P, Nikitin AY (2006) Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res 66(16):7889–7898
18. Patel SJ, Molinolo AA, Gutkind S, Crawford NP (2013) Germline genetic variation modulates tumor progression and metastasis in a mouse model of neuroendocrine prostate carcinoma. PLoS ONE 8(4):e61848
19. Truett GE, Heeger P, Mynatt RL, Truett AA, Walker JA, Warman ML (2000) Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT). Biotechniques 29(1):52–54
20. Hurwitz AA, Foster BA, Allison JP, Greenberg NM, Kwon ED (2001) The TRAMP mouse as a model for prostate cancer. Current protocols in immunology/edited by John E Coligan [et al] Chapter 20:Unit 20 25
21. Williams KA, Lee M, Hu Y et al (2014) A systems genetics approach identifies CXCL14, ITGAX, and LPCAT2 as novel aggressive prostate cancer susceptibility genes. PLoS Genet 10(11):e1004809
22. Smith R, Sheppard K, DiPetrillo K, Churchill G (2009) Quantitative trait locus analysis using J/qtl. Methods Mol Biol 573:175–188
23. Churchill GA, Doerge RW (1994) Empirical threshold values for quantitative trait mapping. Genetics 138(3):963–971
24. Taylor BS, Schultz N, Hieronymus H et al (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18(1):11–22
25. Gao J, Aksoy BA, Dogrusoz U et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6(269):11
26. Faraji F, Pang Y, Walker RC, Nieves Borges R, Yang L, Hunter KW (2012) Cadm1 is a metastasis susceptibility gene that suppresses metastasis by modifying tumor interaction with the cell-mediated immunity. PLoS Genet 8(9):e1002926
27. Dudoit S, van der Laan MJ, Pollard KS (2004) Multiple testing. Part I. Single-step procedures for control of general type I error rates. Stat Appl Genet Mol Biol 3(1):1–69
28. Lee M, Dworkin AM, Lichtenberg J, Patel SJ, Trivedi NS, Gildea D, Bodine DM, Crawford NP (2014) Metastasis-associated protein ribosomal RNA processing 1 homolog B (RRP1B) modulates metastasis through regulation of histone methylation. Mol Cancer Res 12(12):1818–1828
29. Lee M, Dworkin AM, Gildea D, Trivedi NS, Program NCS, Moorhead GB, Crawford NP (2014) RRP1B is a metastasis modifier that regulates the expression of alternative mRNA isoforms through interactions with SRSF1. Oncogene 33(14):1818–1827
30. Prorok PC, Andriole GL, Bresalier RS et al (2000) Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 21(6 Suppl):273S–309S
31. Gohagan JK, Prorok PC, Hayes RB, Kramer BS, Prostate LC, Ovarian Cancer Screening Trial Project T (2000) The prostate, lung, colorectal and ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 21(6 Suppl):251S–272S
32. Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68(4):978–989
33. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2):263–265
34. Tsai RY, McKay RD (2002) A nucleolar mechanism controlling cell proliferation in stem cells and cancer cells. Genes Dev 16(23):2991–3003
35. Ma H, Pederson T (2007) Depletion of the nucleolar protein nucleostemin causes G1 cell cycle arrest via the p53 pathway. Mol Biol Cell 18(7):2630–2635
36. Lin T, Meng L, Li Y, Tsai RY (2010) Tumor-initiating function of nucleostemin-enriched mammary tumor cells. Cancer Res 70(22):9444–9452
37. Okamoto N, Yasukawa M, Nguyen C et al (2011) Maintenance of tumor initiating cells of defined genetic composition by nucleostemin. Proc Natl Acad Sci United States of America 108(51):20388–20393
38. Daum JR, Wren JD, Daniel JJ, Sivakumar S, McAvoy JN, Potapova TA, Gorbsky GJ (2009) Ska3 is required for spindle checkpoint silencing and the maintenance of chromosome cohesion in mitosis. Curr Biol 19(17):1467–1472
39. Gaitanos TN, Santamaria A, Jeyaprakash AA, Wang B, Conti E, Nigg EA (2009) Stable kinetochore-microtubule interactions depend on the Ska complex and its new component Ska3/C13Orf3. EMBO J 28(10):1442–1452
40. Jeyaprakash AA, Santamaria A, Jayachandran U, Chan YW, Benda C, Nigg EA, Conti E (2012) Structural and functional organization of the Ska complex, a key component of the kinetochore-microtubule interface. Mol Cell 46(3):274–286
41. Jiao X, Hooper SD, Djureinovic T, Larsson C, Warnberg F, Tellgren-Roth C, Botling J, Sjoblom T (2013) Gene rearrangements in hormone receptor negative breast cancers revealed by mate pair sequencing. BMC Genom 14:165
42. Eeles R, Goh C, Castro E, Bancroft E, Guy M, Al Olama AA, Easton D, Kote-Jarai Z (2014) The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol 11(1):18–31
43. Al Olama AA, Kote-Jarai Z, Berndt SI et al (2014) A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet 46(10):1103–1109
44. Amin Al Olama A, Kote-Jarai Z, Schumacher FR et al (2013) A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet 22(2):408–415
45. Farber CR (2013) Systems-level analysis of genome-wide association data. G3 3(1):119–129